CD274 and hepatocellular carcinoma: Immunotherapies targeting immune checkpoints in HCC cells, such as antiprogrammed death protein 1 (PD1) and antiprogrammed death ligand 1 (PDL1) inhibitors, have been available in the past [31, 32].